- Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Journal of medicinal chemistry (2008-03-05)
Hong-Yu Li, William T McMillen, Charles R Heap, Denis J McCann, Lei Yan, Robert M Campbell, Sreenivasa R Mundla, Chi-Hsin R King, Elizabeth A Dierks, Bryan D Anderson, Karen S Britt, Karen L Huss, Matthew D Voss, Yan Wang, David K Clawson, Jonathan M Yingling, J Scott Sawyer
PMID18314943
ABSTRACT
In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor 15d (LY2109761) is representative of a novel series of antitumor agents.
MATERIALS